IAΣO does not make a bet on one biomolecule, extracted from one specific microalgae, to treat one particular disease.
We are a bioproduction company with a multi-target, multi-customer platform, manufacturing therapeutic recombinant proteins and vectoring them in the microalgae cell.
Through our "technological ensemble" of microalgae cell lines, USP-DSP processes, cGMP manufacturing, galenic pharmacology, we are the first CDMO (Contract Development & Manufacturing Organization) using eukaryotic microalgae cells to produce biopharmaceuticals, vectored for ready-to-formulate active compounds.
From our proof-of-concept molecules, we are targeting three therapeutic areas: recombinant immunotoxins (3rd generation), our priority - antimicrobial and anti-viral peptides - thermostable peptidic vaccines.